Geron Corp. (NASDAQ:GERN) shares were down 4.5% during mid-day trading on Tuesday . The company traded as low as $2.74 and last traded at $2.74, with a volume of 1,477,298 shares trading hands. The stock had previously closed at $2.87.

A number of research analysts recently issued reports on GERN shares. Zacks Investment Research downgraded Geron Corp. from a “buy” rating to a “hold” rating in a research note on Monday, April 25th. FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a research note on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. Geron Corp. currently has a consensus rating of “Buy” and a consensus price target of $6.20.

The firm has a 50-day moving average of $2.69 and a 200-day moving average of $2.82. The firm has a market capitalization of $436.04 million and a price-to-earnings ratio of 342.50.

Geron Corp. (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The business earned $0.21 million during the quarter, compared to analysts’ expectations of $0.38 million. During the same quarter last year, the business posted ($0.06) earnings per share. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. Analysts anticipate that Geron Corp. will post ($0.23) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Geron Corp. stock. Morgan Stanley boosted its stake in Geron Corp. (NASDAQ:GERN) by 194.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 268,626 shares of the biopharmaceutical company’s stock after buying an additional 177,313 shares during the period. Morgan Stanley owned 0.17% of Geron Corp. worth $1,300,000 as of its most recent SEC filing.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.